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dEuropean Experience on the Practical Use of Levosimendan in
Patients with Acute Heart Failure Syndromes
Ferenc Follath, MD,a,* Fatima Franco, MD,b and José Silva Cardoso, MDc
The novel calcium sensitizer and ATP-dependent potassium channel opener levosi-
mendan has been introduced for routine use in several European countries. Recent
reports on clinical experience confirm the positive hemodynamic results and benefi-
cial clinical effects described in the initial dose-finding and randomized comparative
therapeutic trials in patients with severe low-output heart failure. In addition, studies
in small series of patients with cardiogenic shock after myocardial infarction and/or
surgical interventions and postinterventional myocardial dysfunction (stunning) in-
dicate that the inotropic and vasodilating actions of levosimendan may be of value in
a wider range of indications. Dose recommendations, combination with other drugs,
and potential side effects are discussed in this overview. © 2005 Elsevier Inc. All
rights reserved. (Am J Cardiol 2005;96[suppl]:80G–85G)
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aevosimendan is a new calcium-sensitizing drug that opens
denosine triphosphate–dependent potassium (KATP) channels
ith effects that increase myocardial contraction and cause
asodilation. Compared with other agents for acute heart fail-
re syndromes (AHFS), its main potential advantages are the
mprovement of myocardial contractility without increasing
xygen requirements, reduction of ventricular preload, and an
ntistunning, anti-ischemic effect by opening KATP chan-
els.1–3 This pharmacologic profile of levosimendan offers
ew therapeutic possibilities in patients with AHFS. In initial
ose-finding4,5 and therapeutic trials,6 a rapid and prolonged
emodynamic improvement with an increase in cardiac index,
eduction of pulmonary capillary wedge pressure (PCWP), and
eduction of peripheral vascular resistance without proarrhyth-
ic effects were documented. Furthermore, positive effects on
ong-term survival up to 6 months were observed.6,7
Levosimendan is registered for clinical use in several
ountries in Europe, South America, and Asia. There are an
ncreasing number of reports on practical experiences and
herapeutic successes in different clinical situations. In this
rticle, we summarize recent publications on therapeutic
ndications, dose schedules, outcomes, and tolerance.
ethods
linical reports on levosimendan therapy in patients with
evere decompensated acute or chronic heart failure (HF),
ardiogenic shock after myocardial infarction (MI), or car-
aDepartment of Internal Medicine, University Hospital Zurich, Zurich,
witzerland; bCoimbra University Hospital, Coimbra, Portugal; and cHo-
pital de Sao Joao, Porto, Portugal.
* Address for reprints: Ferenc Follath, MD, Department of Internal
edicine, University Hospital Zurich, Rämistrasse 100, CH 8091 Zurich,
witzerland.
hE-mail address: ferenc.follath@usz.ch.
002-9149/05/$ – see front matter © 2005 Elsevier Inc. All rights reserved.
oi:10.1016/j.amjcard.2005.07.025iac interventions and perioperative administration are re-
iewed. These publications were mostly smaller random-
zed or observational trials, with good descriptions of
atient inclusion criteria, levosimendan administration, and
ethods of clinical and/or hemodynamic evaluation.
herapeutic Efficacy of Levosimendan in Acute Heart
ailure Syndromes
Decompensated low-output heart failure: Decompen-
ated low-output HF is the best documented therapeutic
ndication for levosimendan administered as a single intra-
enous infusion lasting 6 to 24 hours. Patients included in
he dose-finding and comparative clinical trials4–6 were
haracterized by dyspnea (New York Heart Association
NYHA] functional class III to IV) and signs of venous and
ulmonary congestion accompanied by peripheral vasocon-
triction. Hemodynamic inclusion criteria were reduced car-
iac index (2.5 L/min per m2) and increased PCWP (16
m Hg). Patients with systolic blood pressure 90 mm Hg
ere excluded in these initial trials. Bolus injection fol-
owed by a continuous infusion of levosimendan resulted in
rapid increase in cardiac index with simultaneous reduc-
ion of PCWP. There were no arrhythmic complications or
inus tachycardia. A clinical improvement with regression
f dyspnea and fatigue was also observed. Positive effects
ere maintained for 24 to 48 hours after the end of levosi-
endan infusion.
Changes in B-type natriuretic peptide (BNP) levels have
een associated with changes in ventricular filling pres-
ures, and growing evidence suggests that BNP may be both
useful tool to monitor therapy and a powerful prognostic
arker in advanced HF. The treatment of patients with
ecompensated HF with levosimendan was shown to pro-
uce a significant reduction in BNP levels that was associ-
ted with significant improvements in functional status and
emodynamic measures.8–10 An interesting finding among
www.AJConline.org
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81GFollath et al/European Experience on the Practical Use of Levosimendan in Patients with AHFShese studies was that patients whose BNP levels were
owered to 145 pmol/L (500 pg/mL) at discharge had
ignificantly better clinical outcomes than those whose BNP
alues remained at levels 145 pmol/L (500 pg/mL).8,10
Initial trial results could be fully confirmed under routine
linical conditions in an ongoing prospective multicenter
ostlaunch trial in Portugal.11 At present, 120 patients
ith decompensated HF (NYHA class III to IV, left ven-
ricular ejection fraction [LVEF] 0.40) were treated by a
4-hour infusion of levosimendan (0.05 to 0.2 g/kg per
in) with or without initial loading doses. Based on well-
efined uniform criteria for subjective and objective cate-
ories of clinical improvement, a good therapeutic effect
ccurred in 80% of patients without serious adverse events.
n important finding was the marked increase in urinary
utput in initially oliguric patients, with a rapid reduction of
erum creatinine levels. A reduction of serum creatinine was
lso observed in the Levosimendan Infusion Versus Dobut-
mine (LIDO) trial.6 In several patients who were already
eceiving inotropic support with catecholamines, such drugs
ould be stopped and -blockers readministered or initiated.
verall drug tolerance was remarkably good, with the ex-
eption of short episodes of hypotension with decreases of
ystolic blood pressure to 80 mm Hg in up to 33% of the
atients. Hypotension could be treated by dose reduction or
emporary interruption of levosimendan infusion, which
ater could be continued for the remaining 24-hour period.
n additional therapeutic measure in such situations may be
olume replacement, especially in patients with marked
ncreases in diuresis.
Renal insufficiency commonly complicates the treatment of
F because of neurohumoral activation and inadequate organ
erfusion, and it is associated with worse outcomes, including
igher mortality. Levosimendan is hepatically metabolized and
s suitable for use in patients with renal insufficiency. In an-
ther study from Portugal, Franco and colleagues12 have
hown that independent of baseline renal function in patients
ith NYHA functional class IV HF, levosimendan produced
emodynamic benefits while preserving renal status and per-
usion. In this study, which included 41 patients, renal impair-
ent was classified as mild, moderate, or severe, depending on
reatinine clearance. After levosimendan therapy, patients ex-
erienced, on average, a brisk diuresis of similar magnitude
ndependent of the degree of renal impairment (liters per 24
ours, mean [SD]): mild, 2.3 (1.02); moderate, 2.3 (0.84); or
evere, 2.5 (1.96), respectively; p 0.914. Consistent with the
bserved diuresis, mean serum BNP values rapidly decreased
y similar proportions across renal impairment groups at 24
ours, indicating a decrease in myocardial wall stress. There
as no compromise of perfusion or renal function as indicated
y mean serum creatinine, mean arterial pressure, or heart rate
t 24 hours. At discharge, all patients improved by 1 (56%) or
(44%) NYHA classes. The distributions across renal groups
ere not significantly different at 24 hours or at discharge.
A positive clinical experience was also reported byanas and associates,13 who used levosimendan in 18 pa- wients with NYHA class IV HF previously treated with
ong-term intermittent dobutamine infusions. After a final
obutamine infusion at a rate of 10 g/kg per min, levosi-
endan was added with a bolus dose of 6 g/kg for 10
inutes followed by a continuous infusion at a rate of 0.2
g/kg per min for 24 hours. Hemodynamic measurements
ere obtained in all patients. With dobutamine alone, car-
iac index increased by 40% in only 5 of 18 patients
28%), and PCWP did not change. However, at the end of
ombined levosimendan and dobutamine infusions, cardiac
ndex increased 40% in 14 patients (78%, p  0.003) and
emained at a high level, even at 1 week of follow-up, in 11
atients (61%). PCWP also decreased 25% in 8 patients
44%) after 24 hours and was lower than baseline in 7
atients (39%) at the end of 1 week. The combined inotropic
dministration was well tolerated by all patients. At 7 days,
ymptoms also improved in all patients, and NYHA class
ad decreased from 4.0 to 2.94  0.54 (p  0.001). A total
f 15 of the 18 patients could be discharged from the
ospital. Thus, levosimendan may elicit a positive response,
ven in patients whose condition is refractory to dobut-
mine. Furthermore, levosimendan therapy provided clear
utcome benefits, including decreased time to weaning from
notropes, shortened lengths of stay in the hospital and
ntensive care unit, and lower 30-day mortality, when com-
ared with conventional intravenous inotropic agents.
Franco and coworkers14 showed that early addition of
evosimendan to conventional inotropic therapy (dobut-
mine and/or dopamine) in patients with severe hypotension
nd progressive cardiogenic shock improved hemodynamic
tatus and clinical outcomes. Patients who received levosi-
endan therapy (group 1, n  15) required conventional
notrope support for half as long as those who were not
iven levosimendan (group 2, n  11): 62  38 hours for
roup 1 compared with 120  48 hours for group 2, p
0.05. With levosimendan treatment, hospital stay was
ecreased by 1 week (14  5 days compared with 22 
days, p 0.01) and time in the intensive care unit was
ecreased by 50% (5  3 days compared with 9  5 days,
0.05). In this group of patients, in-hospital mortality was
lso decreased 50% because of inclusion of levosimendan in
he therapeutic regimen.
A preliminary clinical experience with repetitive admin-
stration of levosimendan in patients with end-stage HF was
eported by Spargias and colleagues.15 Investigators studied
0 patients hospitalized with acute decompensation refrac-
ory to usual therapeutic agents; 12 of the 20 patients were
emodynamically monitored before, and at the completion
f, levosimendan administration. Right- and left-sided fill-
ng pressures were significantly reduced without changes in
lood pressure and heart rate. In 9 patients, levosimendan
as repeatedly administered 2 to 8 times at intervals of 4 to
weeks. In 6 patients, planned readministration maintained
linical improvement, whereas in 3 patients rehospitalized
or further acute clinical deterioration, repeated treatment
ith levosimendan could not prevent a fatal outcome. In
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82G The American Journal of Cardiology (www.AJConline.org) Vol 96 (6A) September 19, 2005iew of the long-lasting hemodynamic improvement be-
ause of a long-acting metabolite (half-life, approximately
0 hours),16 levosimendan appears to be a suitable drug for
epetitive treatment of patients with advanced HF as a
ridge to cardiac transplantation. Large-scale trials includ-
ng comparison with other drugs used for similar indications
hould be conducted.
From the controlled and observational trials, it can be
oncluded that levosimendan represents an important new
herapeutic option in patients with decompensated low-out-
ut congestive HF. It has advantages over current inotropic
gents, such as prolonged effects after a single 24-hour
nfusion, without complicating cardiac arrhythmias, tachy-
hylaxis, or episodes of drug-induced myocardiac ischemia.
Left ventricular failure in patients with acute coro-
ary artery disease: In the Randomized Study on Safety
nd Effectiveness of Levosimendan in Patients with Left
entricular Failure Due to an Acute Myocardial Infarct
RUSSLAN),7 402 patients with acute MI and clinical and
adiologic signs of left ventricular HF within 5 days were
reated with 4 different doses of levosimendan infused for 6
ours. These patients were compared with a group of 100
atients receiving a placebo infusion in addition to standard
herapy. The aim of this study was to test the tolerance to
his inotropic agent in patients with acute ischemia during
he first 5 days. The incidence of recurrent ischemia and/or
ypotension was similar in the levosimendan and placebo
roups. Clinical worsening with the need for additional
reatment with intravenous diuretics or other inotropes was
ignificantly less frequent in the levosimendan group than in
he placebo group (7.2% vs 13.7%, p  0.03). At 14 days,
ortality was lower after levosimendan than after placebo
11.7% vs 19.6%; hazard ratio, 0.56; 95% confidence inter-
al [CI], 0.33 to 0.95; p  0.031). Mortality reduction was
aintained up to 180 days (22.6% vs 31.4%; hazard ratio,
.67; 95% CI, 0.45 to 1.0; p  0.053). However, an impor-
ant experience in this study was a poor tolerance of the
ighest levosimendan dose level of 0.4 g/kg per min. This
ose increased the incidence of hypotension and/or isch-
mia up to 19% compared with 10.7% to 12% in the 2
roups receiving the lower (0.1 or 0.2 g/kg per min) dose
evosimendan and after placebo (10.8%). Thus, the impor-
ance of the upper dose limit of 0.2 g/kg per min should be
ecognized in all patients with acute myocardial ischemia.
A recent report by Sonntag and associates17 illustrates
he potential utility of levosimendan in the prevention of
yocardial stunning after coronary reperfusion. In 18 pa-
ients with acute coronary syndrome, levosimendan was
dministered at a dose of 24 g/kg infused over 20 minutes
mmediately after the completion of angioplasty. This treat-
ent reduced the number of hypokinetic segments signifi-
antly as compared with a placebo infusion. Levosimendan-
reated patients also had a lower left ventricular end-
iastolic volume and higher LVEF. The myocardial
rotection might be a result of the KATP channel–opening iffects of levosimendan. This clinical observation is in
ccordance with the experimental data of Kersten and co-
orkers18 who showed a reduced myocardial infarct size in
ogs undergoing coronary artery occlusion.
Cardiogenic shock: In the initial dose-finding and ther-
peutic trials in patients with decompensated HF, a systolic
lood pressure 90 mm Hg was an exclusion criterion. In
iew of its vasodilatory and potential blood pressure–low-
ring effects, levosimendan alone is not a drug of first
hoice in cardiogenic shock. There are, however, several
ecent clinical observations indicating that levosimendan
an improve hemodynamics, even in patients with cardio-
enic shock, if it is combined with norepinephrine to main-
ain adequate perfusion pressures. Delle Karth and col-
eagues19 administered levosimendan to 10 patients with
ardiogenic shock after MI or cardiac surgery who did not
mprove after revascularization. Patients then underwent
ntra-aortic balloon counterpulsation and infusion of cat-
cholamines. First, norepinephrine was given to maintain
ean arterial pressure at a level 65 mm Hg, then a levo-
imendan infusion was added at a dose of 0.1 g/kg per min
ithout a bolus and continued for 24 hours; 7 of 10 patients
ere also mechanically ventilated. Patients also received
olume administration to maintain cardiac filling pressures.
evosimendan treatment resulted in a significant increase in
ardiac output together with a decrease in systemic vascular
esistance. A total of 4 patients could be weaned from
atecholamines, and all survived up to 6 months. The 6
onsurvivors died of refractory cardiogenic shock (n  4),
ntracerebral bleeding (n 1), or mesenteric infarction (n
). In another study, Lehmann and associates20 described
he use of levosimendan in 18 patients after resuscitation
fter acute MI. Patients underwent emergency surgical re-
ascularization followed by a combined treatment with le-
osimendan and norepinephrine. All patients in these series
ould be weaned from cardiopulmonary bypass, and 8 sur-
ived without the occurrence of multiorgan failure. A com-
arable experience was reported by Labriola and cowork-
rs21 who treated 11 patients with cardiogenic shock after
urgical interventions. In 8 patients (73%), cardiac index
as increased by 30%, and PCWP was reduced to 18
m Hg within 3 hours after the start of levosimendan
nfusion. There are also several case reports on successful
reatment of patients with various causes of cardiogenic
hock by Zobel and colleagues,22 and Benlolo and associ-
tes,23 and in a case of sepsis, by Matejovic and cowork-
rs.24 The above reports suggest that levosimendan may be
uccessfully used in combination with catecholamines, such
s norepinephrine, to treat cardiogenic shock. Nevertheless,
ormal controlled and comparative studies are necessary to
efine the place of levosimendan in such patients.
Perioperative treatment in patients undergoing car-
iac surgery: Initial hemodynamic studies by Lilleberg et
l25 have shown that levosimendan improves hemodynam-
cs in patients after coronary artery bypass grafting. More
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83GFollath et al/European Experience on the Practical Use of Levosimendan in Patients with AHFSecently, Plochl and Rajek26 also described significant in-
reases in cardiac output and stroke volume with decreases
n systemic vascular resistance in 10 critically ill postoper-
tive patients. In a small randomized study, Nijhawan and
olleagues27 compared the hemodynamic effects of 2 doses
f levosimendan (0.2 or 0.3 g/kg per min infused for 6
ours) with that of placebo after cardiopulmonary bypass.
t 15 minutes after the end of cardiopulmonary bypass,
evosimendan increased cardiac output and reduced sys-
emic vascular resistance without hypotension or tachycar-
ia. The investigators suggested that the dose of 0.2 g/kg
er min would be sufficient because the clinical outcome
as not different in the 2 levosimendan-treated groups.
arisin and associates28 tested the hypothesis that levosi-
endan could prevent ischemic myocardial impairment
uring and after off-pump coronary bypass grafting. In a
andomized study, 31 patients were treated with a low (12
g/kg) or a high (24 g/kg) dose of levosimendan or pla-
ebo administered over 10 minutes started 20 minutes be-
ore the operation. Cardiac output and LVEF were signifi-
antly higher and systemic vascular resistance was
ignificantly lower in patients receiving levosimendan com-
ared with those receiving placebo. Again, the lower dose
as regarded as sufficient to improve hemodynamics and to
void hypotension and tachycardia. In this study, all pa-
ients also received an initial volume load of 500 mL
efore levosimendan administration.
These perioperative and postoperative studies in cardiac
urgical patients indicate that levosimendan is a potentially
seful drug to prevent and/or improve postoperative isch-
mic cardiac depression. A controlled, large-scale trial is
eeded to give a definitive answer about the role of levosi-
endan in such patients.
Dose recommendations: The optimum dose regimen
nd duration of administration of levosimendan should be
ased on the pharmacokinetic properties of levosimendan
nd its main pharmacologically active metabolite. The
alf-life of unchanged levosimendan is 1 hour, which
eans that a steady-state concentration is achieved
ithin 4 hours after the beginning of infusion. However,
he formation of the active metabolite (OR-1896), with a
alf-life of approximately 80 hours, continues to increase
ven after the end of a 24-hour infusion.29 Because of the
rogressive accumulation of the metabolite, pharmaco-
ogic effects continue to increase if the drug is given for
24 hours. Kivikko and coworkers30 infused levosimen-
an for 7 days at doses of 0.05 or 0.1 g/kg per min to
atients with chronic HF. At the end of the infusion at 1
eek, there were significant dose-dependent increases in
eart rate (15 to 25 beats per minute), and systolic and
iastolic blood pressures decreased by 1114 mm Hg
nd 1110 mm Hg, respectively. Side effects occurred in
6 of 24 patients: 1 patient experienced worsening of HF
ymptoms, 4 patients had cardiac arrhythmias, 3 had pypotension, headache, and dizziness, and 2 reported
ngina pectoris. Therefore, prolonged infusions 24
ours should be avoided.
A controversial question is whether a loading dose is
ecessary to start levosimendan therapy. The loading
ose is only indicated if a rapid therapeutic effect is
equired within the first hours before the full effect of
nchanged levosimendan is reached by a continuous in-
usion (about 4 hours). In addition, the size of the loading
ose should be adapted to the individual situation and can
ary between 6 g/kg and 24 g/kg over 10 to 20
inutes. A loading dose should be avoided in patients
ith systolic blood pressure 90 mm Hg. The optimum
aintenance dose may range from 0.05 to 0.2 g/kg per
in. As shown by the RUSSLAN trial,7 a dose 0.2
g/kg per min may result in hypotension, tachycardia,
nd myocardial ischemia in patients who have had a
ecent MI.
ombination with Other Drugs
s previously discussed, levosimendan enhances the he-
odynamic effects of dobutamine. It can be combined
ith norepinephrine in patients with initially low systolic
lood pressure to maintain adequate organ and tissue
erfusion. A practical advantage of levosimendan is that
ts effects are not reduced or prevented by concomitant
-blocker therapy.6 Under the protection of levosimen-
an, -blockers can be started in patients with advanced
F.
olerability
n general, levosimendan has been shown to be well
olerated, with most of its potential adverse effects being
econdary to its vasodilating properties. Adverse events
re dose related. In 972 patients treated with intravenous
evosimendan in the initial clinical trials, headache oc-
urred in 8.7% and hypotension in 6.5% of patients.31
mong the laboratory parameters, slight reductions in
ed blood cell count, hematocrit, and hemoglobin
10%), as well as small reductions of serum potassium,
ere also described in 5% of patients. In contrast, serum
reatinine levels significantly improved, even in patients
ith initially reduced renal function. Long-term electro-
ardiographic recordings showed no proarrhythmic ef-
ects.32
onclusion
he calcium sensitizer and KATP channel opener levosi-
endan offers new therapeutic possibilities for AHFSatients, providing symptomatic and hemodynamic im-
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84G The American Journal of Cardiology (www.AJConline.org) Vol 96 (6A) September 19, 2005rovements within a few hours after the beginning of
ntravenous administration. A summary of the clinical
se of levosimendan is shown in Table 1. In patients with
HFS treated with levosimendan, a survival benefit com-
ared with dobutamine was observed in clinical trials. In
everal countries, the drug is already routinely used in
atients with HF requiring inotropic support. Other po-
ential indications for levosimendan include myocardial
epression and stunning after coronary bypass operations
r catheter revascularization. However, controlled trials
f sufficient size are still lacking for these applications.
nitial experience with levosimendan in combination with
orepinephrine in patients with cardiogenic shock is also
ncouraging, but again, comparative trials are needed.
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